Its broad scope brings together critical knowledge from many disciplines, ranging from process technology to pharmacology to intellectual property issues.
After introducing the overall early development workflow, the critical steps of early drug development are described in a sequential and enabling order: the availability of the drug substance and that of the drug product, the prediction of pharmacokinetics and -dynamics, as well as that of drug safety. The final section focuses on intellectual property aspects during early clinical development. The emphasis throughout is on recent case studies to exemplify salient points, resulting in an abundance of practice-oriented information that is usually not available from other sources.
Aimed at medicinal chemists in industry as well as academia, this invaluable reference enables readers to understand and navigate the challenges in developing clinical candidate molecules that can be successfully used in phase one clinical trials.
Table of Contents
Contents to Volume 1
Preface xv
A Personal Foreword xix
1 Early Drug Development: Progressing a Candidate Compound to the Clinics 1
Fabrizio Giordanetto
References 7
Part I Drug Substance 9
2 Early Phase API Process Development Overview 11
J. Christopher McWilliams and Mark Guinn
3 The Discovery/Development Transition 31
Christopher M. Cimarusti and David R. Kronenthal
4 Active Pharmaceutical Ingredient Cost of Goods: Discovery to Early Development 49
Neal G. Anderson and Todd D. Nelson
5 New Technologies in Process Development 73
Peter W. Sutton, Joseph P. Adams, Charles Wade, and Katherine Wheelhouse
6 Vortioxetine and Early Drug Development Considerations at the Interface of R&D 125
Morten Jørgensen, Kim Christensen, Martin Juhl, and Benny Bang-Andersen
7 Development of a Practical Synthesis of 4′-Azido-2′;;-Methyl-2′-Desoxycytosine and Its Prodrugs as HCV Chemotherapeutic Agents 145
Sébastien Lemaire, Tom Govaerts, and Vittorio Farina
Part II Drug Product 169
8 Solubility, Permeability, and Their Interplay 171
Avital Beig, Milica Markovic, and Arik Dahan
9 Solid-State Properties 203
Si-Wei Zhang, Robert F. Dunn, and Alfred Y. Lee
10 Salt and Cocrystal Screening 229
Ann Newman, Cen Chen, and Carlos Sanrame
11 Particle Size Reduction: From Microsizing to Nanosizing 271
Dedong Wu and Beth A. Sarsfield
12 Early Drug Development: From a Drug Candidate to the Clinic 305
Mark McAllister, Joanne Bennett, John Davis, Brian Henry, and MeiWong
13 A Practical Guide for the Preparation of Drug Nanosuspensions for Preclinical Studies: Including In Vivo Case Studies 333
Kalle Sigfridsson, Urban Skantze, Pia Skantze, and Lennart Lindfors
Contents to Volume 2
A Personal Foreword xxiii
Part III Pharmacokinetics and Pharmacodynamics 365
14 Integration of Pharmacokinetic and Pharmacodynamic Reasoning and Its Importance in Drug Discovery 367
Johan Gabrielsson and Stephan Hjorth
15 Prediction of Human Pharmacokinetics and Pharmacodynamics 399
Ulf Bredberg
16 Translational Modeling and Simulation for Molecularly Targeted Small Molecule Anticancer Agents: Case Studies of Multiple Tyrosine Kinase Inhibitors, Crizotinib and Lorlatinib 433
Shinji Yamazaki
17 Informing Decisions in Discovery and Early Development Research Through Quantitative and Translational Modeling 467
Tjerk Bueters, Christopher R. Gibson, Prajakti A. Kothare,Mallika Lala, Eric M. Parker,Matthew L. Rizk, Daniel Tatosian, Maria E. Trujillo, Pavan Vaddady, and Sandra A.G. Visser
Contents to Volume 2
Part IV Toxicology 497
18 Preclinical Toxicology Evaluation 499
Sara Moses, Ulf Andersson, and Martin Billger
19 Nonclinical Safety Pharmacology 527
Bruce H. Morimoto
20 Early Drug Development 549
Luis G. Valerio Jr.
21 Addressing Genotoxicity Risk in Lead Optimization: A PDE10A Inhibitor Case Study 581
Bie M. P. Verbist, Marjolein Crabbe, Freddy Van Goethem, and Hinrich W. H. Göhlmann
22 The Integrated Optimization of Safety and DMPK Properties Enabling Preclinical Development: A Case History with S1P1 Agonists 603
Simon Taylor
23 From TRAIL to ONC201: Case Study on the Safety Benefit of Developing Targeted Agents Against Cancer-selective Pathways 631
Christina Leah B. Kline, JessicaWagner, Amriti Lulla,Marie D. Ralff, Avital Lev, Lanlan Zhou, Varun V. Prabhu, Martin Stogniew, Lee Schalop,Wolfgang Oster, Joshua E. Allen, andWafik S. El-Deiry
Part V Intellectural Property 647
24 Patent Law Relevant to Early Drug Development 649
Joanna T. Brougher Esq.,MPH and Audrey Ogurchak
25 Patent Protection Strategy 667
Mark A. Borsos
26 Intellectual Property: The Patent Landscape Viewed from Generic and Originator Perspectives 691
Jonathan D.M. Atkinson D.Phil; EPA; C Chem. FRSC
27 Patent Considerations in Collaborative Drug Development 721
Mary Anne Armstrong
Index 749
